Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0019209 (
hepatomegaly
)
5,798
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Conjugated linoleic acid
(
CLA
) is a naturally occurring group of dienoic derivatives of linoleic acid found in beef and dairy products.
CLA
has been reported to reduce body fat. To examine the mechanism(s) of
CLA
reduction of fat mass, female C57BL/6J mice were fed standard semipurified diets (10% fat of total energy) with or without
CLA
(1% wt/wt). Terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick endlabeling (TUNEL) and DNA fragmentation analysis revealed that fat-mass decrease by
CLA
was mainly due to apoptosis. Tumor necrosis factor (TNF)-alpha and uncoupling protein (UCP)-2 mRNA levels increased 12- and 6-fold, respectively, in isolated adipocytes from
CLA
-fed mice compared with control mice. Because it is known that TNF-alpha induces apoptosis of adipocytes and upregulates UCP2 mRNA, a marked increase of TNF-alpha mRNA with an increase of UCP2 in adipocytes caused
CLA
-induced apoptosis. However, with a decrease of fat mass,
CLA
supplementation resulted in a state resembling lipoatrophic diabetes: ablation of brown adipose tissue, a marked reduction of white adipose tissue, marked
hepatomegaly
, and marked insulin resistance.
CLA
supplementation decreased blood leptin levels, but continuous leptin infusion reversed hyperinsulinemia, indicating that leptin depletion contributes to the development of insulin resistance. These results demonstrate that intake of
CLA
reduces adipose tissue by apoptosis and results in lipodystrophy, but hyperinsulinemia by
CLA
can be normalized by leptin administration.
...
PMID:Conjugated linoleic acid supplementation reduces adipose tissue by apoptosis and develops lipodystrophy in mice. 1096 38
Conjugated linoleic acid
(
CLA
) is a naturally occurring group of dienoic derivatives of linoleic acid found in beef and dairy products. However, when 1 g
CLA
/100 g diet was given to mice in a low fat diet (4 g fat/100 g diet), they showed a marked decrease in fat mass, but demonstrated symptoms of lipoatrophic diabetes, i.e., marked
hepatomegaly
and insulin resistance. In this study, to determine whether the decrease in adipose tissue was responsible for these adverse effects, mice were fed different doses of
CLA
and dietary fat. In Experiment 1, mice were fed different doses of
CLA
(0, 0.1 and 1 g
CLA
/100 g diet) in a fixed 4 g fat/100 g diet; in those fed 0.1 g
CLA
, subcutaneous white adipose tissue (WAT) weight was 48% lower than in mice fed 0 g
CLA
. The mice fed 0.1 g
CLA
did not exhibit
hepatomegaly
and insulin resistance. In Experiment 2, mice were fed for 5 mo different amounts of dietary fat (4, 13 and 34 g fat/100 g diet) in 0 or 1 g
CLA
/100 g diet; in mice fed 1 g
CLA
with 34 g fat, retroperitoneal and subcutaneous WAT weights were 76 and 79% lower, respectively, than those of mice fed 0 g
CLA
with 34 g fat. Mice fed 1 g
CLA
in the diet with 34 g fat had normal plasma insulin concentrations and a 45% greater liver weight. These data suggested that the percentage of
CLA
in dietary fat might be a determinant of
CLA
-mediated lipodystrophy.
...
PMID:Increasing the amount of fat in a conjugated linoleic acid-supplemented diet reduces lipodystrophy in mice. 1277 19
Nonalcoholic fatty liver disease (NAFLD) is the preferred term to describe the spectrum of liver damage ranging from hepatic steatosis to steatohepatitis, liver fibrosis, and cirrhosis, and it is emerging as the most common liver disease in industrialized countries. Thus, the discovery of food components that would ameliorate NAFLD is of interest.
Conjugated linoleic acid
(
CLA
), a mixture of positional and geometric isomers of linoleic acid, has attracted considerable attention because of its potentially beneficial biological effects both in vitro and in vivo. We tested whether dietary
CLA
protects Zucker (fa/fa) rats from hepatic injury. After 8 wk of feeding,
hepatomegaly
, hepatic triglyceride (TG) accumulation, and elevated hepatic injury markers in plasma were markedly alleviated in
CLA
-fed Zucker rats compared with linoleic acid-fed (control) rats. These effects were attributed in part to the enhanced hepatic activities of carnitine palmitoyltransferase, a key enzyme of fatty acid beta-oxidation, and microsomal TG transfer protein, an important factor for lipoprotein secretion due to the
CLA
diet. We previously reported that the severe hyperinsulinemia in control Zucker rats was attenuated in
CLA
-fed rats due to an enhanced level of plasma adiponectin, which improves insulin sensitivity. In the present study, the adiponectin concentration was increased and the mRNA expression of tumor necrosis factor-alpha, an inflammatory cytokine, was markedly suppressed in the liver of
CLA
-fed Zucker rats. We speculate that the enhanced level of liver adiponectin may prevent the development and progression of NAFLD in
CLA
-fed Zucker rats.
...
PMID:Dietary conjugated linoleic acid alleviates nonalcoholic fatty liver disease in Zucker (fa/fa) rats. 1562 25
Conjugated linoleic acid
(
CLA
) is consumed widely as a supplement. It causes
hepatomegaly
in animals, but toxicological data in humans are limited. We therefore studied the effect of a high daily intake of
CLA
on liver and kidney function in healthy subjects. Twenty subjects received 14.6 g cis-9,trans-11
CLA
and 4.7 g trans-10,cis-12
CLA
isomers a day for 3 weeks. Liver and kidney function was measured at 0, 3, 7, 10, 16, and 21 days. Mean values of all tests remained within normal limits. Lactate dehydrogenase (mean+/-SD) increased from 290.9+/-43.6 to 322.5+/-60.7 U/L (p=0.04) on day 21. One subject exceeded the upper limit of normal of 450 U/L on day 21, to 472 U/L and another showed an isolated elevation to 555 U/L on day 7. Gamma-glutamyltranspeptidase increased from 12.1+/-5.9 to 13.5+/-6.2U/L (p=0.002). No one exceeded the upper limit of 50 U/L for men and 40 U/L for women. A daily intake of 19.3 g
CLA
for 3 weeks does not produce clinically relevant effects on markers of liver and kidney function in healthy volunteers.
...
PMID:A high intake of conjugated linoleic acid does not affect liver and kidney function tests in healthy human subjects. 1993 29